The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, MBBCh
Published Online: 7:27 PM, Wed October 1, 2014
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.

Clinical Pearls
  • The study showed that about 39% (12 of 31) of patients in the enzalutamide arm had AR-V7 detected in their circulating tumor cells.
  • Every patient taking enzalutamide that had AR-V7 did not obtain a PSA response to enzalutamide.
  • In the abiraterone arm, 19% (6 of 31) were found to have AR-V7.
  • Similarly, all of these patients demonstrated resistance to abiraterone. ​

<<< View more from the 2014 ESMO Congress

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.